Venus Remedies has received grant of market authorisation from COFEPRIS the Drug Regulatory Authority of Mexico, for its Meropenem 500mg and Meropenem 1000mg in Mexico. The company is planning to launch the product in Mexico within the first quarter of fiscal year 2013-2014.
This grant from COFEPRIS (La Comision Federal para la Protecciob contra Riesgos Sanitarios) the Latin America’s most stringent regulatory authority, is further endorsement to Venus Remedies’ R&D capabilities and its expertise in developing world class products. Market authorisation for Meropenem will enable Venus Remedies to launch its first product in Mexico and will strengthen its position in Latin America where Venus is currently exporting to various countries of LAC such as Columbia, Peru, Guatemala, Dominican Republic, Jamaica, Bahamas and the Caribbean. A market authorisation grant at a point of time when the innovator’s product has already gone off patent is going to be an advantage for the company.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
